Navigation Links
Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer
Date:6/17/2009

Researchers have identified a new candidate tumor suppressor gene in colorectal cancer and examined its use as a potential biomarker in stool samples, according to a new study published online June 17 in the Journal of the National Cancer Institute.

In the study, Manon van Engeland, Ph.D., of the Department of Pathology at Maastricht University Medical Center in the Netherlands, and colleagues examined N-Myc downstream-regulated gene 4 (NDRG4) as a novel tumor suppressor and biomarker.

The researchers analyzed NDRG4 promoter methylation and expression in human colorectal cancer cell lines, noncancerous colon mucosa, and colorectal cancer tissue. Quantitative methylation-specific polymerase chain reaction was used to examine NDRG4 promoter methylation as a biomarker in fecal DNA from 75 colorectal cancer patients and 75 control subjects.

The researchers found that NDRG4 promoter methylation was more prevalent in colorectal cancers than in noncancerous colon mucosa. Its mRNA and protein expression were decreased in colorectal cancer tissue compared with noncancerous colon mucosa. A methylation-specific polymerase chain reaction assay for NDRG4 promoter methylation in stool identified the presence of colorectal cancer in 53% of colorectal cancer cases and correctly categorized a subject as cancer free 100% of the time.

"In conclusion, to our knowledge, this is the first study to describe a tumor suppressor role for NDRG4 in cancer," the authors write. "Our data indicate that NDRG4 promoter methylation is potentially useful as a sensitive and specific noninvasive pre-selection modality for identifying individuals at risk for colorectal cancer for whom colonoscopy is recommended."

In an accompanying editorial, Gad Rennert, M.D., Ph.D., of the Carmel Medical Center and Technion in Haifa, Israel, discusses the concept of molecular testing of stool for early detection of colorectal cancer and where such testing stands today.

"Genetic diagnosis of colorectal cancers and meaningful adenomas has now reached a new phase that, when further fine-tuned, may carry the promise of becoming a suitable and affordable means of prevention and early detection of colorectal cancer in the general population," he writes.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional ... ensures the integrity of biological samples while operating at ultra-high pressures of 20,000 ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost ... Part D a decade ago, according to The Senior Citizens League (TSCL). ... they are coping with rapidly rising costs. “The implications are chilling, particularly for ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury ... injury may be one of many possible sources: sports, car accidents, falls, work ... , Mastering Rehab Solutions for the Complexities of Concussions is designed ...
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness Month, and ... scans throughout the month to the American Heart Association, New Mexico chapter. , A ... heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... announces today the continuation of the ‘Pay It Forward’ program into 2016. BioPlus ... received at our specialty pharmacy. , “Since our Pay It Forward program ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 --> ... and Companion Diagnostic Market to 2019 - Strategic ... research report indicates that the core personalized medicine ... 2020 growing at a CAGR of 8.74%. This ... targeted therapeutics and is dominated by oncology, cardiovascular ...
(Date:2/10/2016)... , February 10, 2016 ... M 1 receptor selectivity   ... technology, which has entered clinical development as a ... dementia and schizophrenia.   --> 1 ... which has entered clinical development as a new ...
(Date:2/9/2016)... 9, 2016  Misonix, Inc. (NASDAQ: MSON ... manufactures and markets innovative therapeutic ultrasonic products for ... surgery, laparoscopic surgery and other surgical applications, today ... the first half of fiscal year 2016 ended ... --> Highlights for the second ...
Breaking Medicine Technology: